Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Guizhou Meixinda Medical Technologies Co. Ltd. currently manages a focused patent portfolio within the Biotechnology & Pharmaceuticals technology area. The presence of 1 pending office action indicates a singular active prosecution thread at this time. This matter is handled by 1 distinct examiner, which suggests that the company's current interactions with the patent office are highly centralized. Furthermore, the portfolio is restricted to 1 distinct art unit, reflecting a specific technical niche for its pending intellectual property and a lack of cross-disciplinary filings.
The busiest examiner for this portfolio is CLARKE, TRENT R, who is responsible for 1 busiest examiner pending office action. Because this examiner accounts for the 1 pending office action, the entirety of the company's current workload is under a single individual's review. For a practitioner, this concentration means that the outcome of the portfolio's active prosecution depends on the specific interpretations of this one examiner within their assigned art unit. The alignment of 1 distinct examiner with 1 distinct art unit confirms that the company is not currently navigating multiple simultaneous channels at the patent office, which simplifies the administrative burden of tracking active matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CLARKE, TRENT R | 1 | 42.2% | +24.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17905083 | DEVICES AND COMPONENTS FOR AUTOMATED TISSUE PROCESSING AND STAINING AND USES THEREOF | CLARKE, TRENT R | 44d overdue |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17905083 | DEVICES AND COMPONENTS FOR AUTOMATED TISSUE PROCESSING AND STAINING AND USES THEREOF | CLARKE, TRENT R | 1651 | §103DP | Final Rejection | 44d overdue | Pending | Aug 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGuizhou Meixinda Medical Technologies Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Trent R Clarke has the most, with 1 of Guizhou Meixinda Medical Technologies Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.